Enhanced adherence to HCV therapy with higher dose ribavirin formulation: Final analyses from the ADHERE registry

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 4, 2010, Pages 535-542

  Alam, I ^a   Stainbrook, T ^b   Cecil, B ^c   Kistler, K D ^d  

^a Austin Cancer Center   (United States)

^b DuBois Regional Medical Center   (United States)

^c Hepatitis C Treatment Centers   (United States)

^d ProSanos Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAPAK; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TABLET; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RIBAVIRIN;

EID: 77954746102     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04381.x     Document Type: Article

References (35)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med 2006 144:705 714.
2. World Health Organization. Hepatitis C. Wkly Epidemiol Rec 1997 72:65 9.
3. Management of hepatitis C. NIH Consens State Sci Statements 2002 19:1 46.
4. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010 52:652 657.
5. Yu ML, Lin SM, Chaung WL, et al. A sustained virological response to interferon or interferonribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006 11:985 994.
6. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus. Clin Gastroenterol Hepatol 2010 8:280 288.
7. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral Therapy for Cirrhotic Hepatitis C: association with Reduced Hepatocellular Carcinoma Development and Improved Survival. Ann Intern Med 2005 142:105 114.
8. Lo Re V III., Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009 48:186 193.
9. Broers B, Helbling B, François A, et al. Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005 42:323 328.
10. Solà R, Galeras JA, Montoliu S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses 2006 22:393 400.
11. Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat 2005 12:91 5.
12. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140:346 355.
13. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347:975 982.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358:958 965.
15. Cacoub P, Ouzan D, Melin P, et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol 2008 28:14.
16. Smith SR, Wahed AS, Kelley SS, et al. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007 41:1116 1123.
17. Weiss JJ, Bhatti L, Dieterich DT, et al. Hepatitis C patients' self-reported adherence to treatment With pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008 28:289 293.
18. Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 2009 25:2765 2775.
19. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007 15:257 263.
20. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009 4:1089 1096.
21. Tindall WN. New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. Am J Health Syst Pharm 2009 66:451 457.
22. Bangsberg DR, Wu Y, Yuan Y, Iloeje U. Pill burden predicts adherence, regimen discontinuation or switch, viral load and CD4 cell response in a nationwide US sample of HIV+ antiretroviral naive people on protease inhibitor (PI) therapy. Antivir Ther 2003 8 (Suppl.1): Abstract no. 757.
23. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDS 2009 23:903 914.
24. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended releaselamivudineefavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008 9:164 176.
25. McHutchison J, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123:1061 1069.
26. Mitra D, Davis KL, Beam C, et al. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health 2010 [Epub ahead of print].
27. Davis GL, Wong JB, McHutchison JG, et al. Early virology response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38:645 652.
28. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2009 31:502 508.
29. Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009 30:14 27.
30. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 37:846 857.
31. Palmer M. Improvement in treatment adherence in patients with chronic hepatitis C. Practical Gastroenterology 2008:31 42.
32. Sabaté E, ed. Adherence to long-term therapies: evidence for action.
33. Pozza R, Barakat F, Barber E. Adherence to therapy: challenges in HCV-infected patients. Current Hepatitis Reports 2007 6:160 168.
34. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008 31:213 224.
35. New Report: Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease. Available at: http://www.vrtx.com/ millimanreport.html. Accessed January 2010.